Tursi, Antonio
 Distribuzione geografica
Continente #
NA - Nord America 300
EU - Europa 229
AS - Asia 38
SA - Sud America 8
AF - Africa 1
Totale 576
Nazione #
US - Stati Uniti d'America 298
IT - Italia 67
SE - Svezia 51
IE - Irlanda 28
FR - Francia 24
DE - Germania 21
CN - Cina 16
UA - Ucraina 13
GB - Regno Unito 9
CO - Colombia 8
FI - Finlandia 7
IN - India 7
KR - Corea 6
BE - Belgio 3
IL - Israele 2
IR - Iran 2
BG - Bulgaria 1
BH - Bahrain 1
BZ - Belize 1
CA - Canada 1
CZ - Repubblica Ceca 1
JP - Giappone 1
LI - Liechtenstein 1
NG - Nigeria 1
PH - Filippine 1
PL - Polonia 1
RO - Romania 1
RU - Federazione Russa 1
SG - Singapore 1
TR - Turchia 1
Totale 576
Città #
Chandler 97
Ashburn 29
Dublin 26
New York 22
Milan 17
Marseille 13
Rome 9
Bogotá 8
Beijing 7
Princeton 7
Pune 7
Boston 6
Jacksonville 6
Seoul 6
Fairfield 5
Houston 5
Helsinki 4
Redwood City 4
Seattle 4
Wilmington 4
Ann Arbor 3
Brussels 3
Chelsea 3
Monte Argentario 3
San Diego 3
San Mateo 3
Washington 3
Boardman 2
Bremen 2
Busto Arsizio 2
Cattolica 2
Chicago 2
Edinburgh 2
Hangzhou 2
Jiaxing 2
Lawrence 2
Los Angeles 2
Munich 2
Nanjing 2
Paris 2
Pescara 2
Saint-Fons 2
Alexandria 1
Andover 1
Arezzo 1
Arzachena 1
Augusta 1
Belize City 1
Brdo 1
Bucharest 1
Capoliveri 1
Changsha 1
Chiswick 1
Cormeilles-en-Parisis 1
Dearborn 1
Frankfurt am Main 1
Gdansk 1
Grottaglie 1
Hebei 1
Huskvarna 1
Istanbul 1
Kish 1
Lagos 1
Lappeenranta 1
Las Vegas 1
Leawood 1
London 1
Massa 1
Montreal 1
Nanchang 1
Olongapo City 1
Sofia 1
Tel Aviv 1
Tokyo 1
Torre del Lago Puccini 1
Trieste 1
University Park 1
Vaduz 1
Villongo 1
Woodbridge 1
Totale 375
Nome #
Effect of moderate and heavy alcohol consumption on intestinal transit time 80
Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon. 74
Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease 58
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 55
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 49
Intestinal Microbiome Modulation During Coronavirus Disease 2019: Another Chance to Manage the Disease? 38
The “dica” endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists 32
Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase 32
Response to Jackson et al 30
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 29
Assessment of small intestinal bacterial overgrowth and methane production in patients on chronic proton-pump inhibitor treatment: prevalence and role of rifaximin in its management in primary care 27
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study 21
Microbiota Composition in Diverticular Disease: Implications for Therapy 16
Microbiota Composition in Diverticular Disease: Implications for Therapy 15
When to Perform a Colonoscopy in Diverticular Disease and Why: A Personalized Approach 10
SARS-CoV-2 infection as a potential trigger factor for de novo occurrence of inflammatory bowel disease 10
Prognostic performance of the ‘DICA’ endoscopic classification and the ‘CODA’ score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study 8
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study 6
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy 4
Diverticular Inflammation and Complication Assessment classification, CODA score and fecal calprotectin in clinical assessment of patients with diverticular disease: A decision curve analysis 3
Prevalence and Natural History of Segmental Colitis Associated With Diverticulosis 2
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study 2
Totale 601
Categoria #
all - tutte 3.368
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.368


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20194 0 0 0 0 0 0 0 0 0 3 0 1
2019/202021 5 0 2 0 1 0 4 1 1 0 4 3
2020/202123 0 2 7 3 3 1 1 0 2 0 3 1
2021/202281 3 2 0 0 1 1 2 4 3 18 23 24
2022/2023237 27 27 11 40 13 25 16 26 19 10 16 7
2023/2024188 9 43 23 17 8 31 21 4 18 14 0 0
Totale 601